409 related articles for article (PubMed ID: 25043540)
21. [Combined treatment: regimens, indications and safety profile].
Muñiz Grijalvo O; Villar Ortiz J
Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
[TBL] [Abstract][Full Text] [Related]
22. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
Milionis H
Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
[TBL] [Abstract][Full Text] [Related]
23. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
25. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M
Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interactions between statins and fibrates.
Corsini A; Bellosta S; Davidson MH
Am J Cardiol; 2005 Nov; 96(9A):44K-49K; discussion 34K-35K. PubMed ID: 16291014
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
28. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
29. Do persons with stroke benefit from statin-fibrate combination therapy?
Castilla-Guerra L; Fernandez-Moreno Mdel C
Eur J Intern Med; 2015 Mar; 26(2):148-9. PubMed ID: 25620642
[No Abstract] [Full Text] [Related]
30. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy studies].
Pedro-Botet J; Flores-Le Roux JA
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
Choi HD; Shin WG; Lee JY; Kang BC
Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
[TBL] [Abstract][Full Text] [Related]
33. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
34. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q; Ren J; Chen H; Lee C; Liang W
Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878
[TBL] [Abstract][Full Text] [Related]
35. [Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Núñez-Cortés JM
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():31-4. PubMed ID: 25043545
[TBL] [Abstract][Full Text] [Related]
36. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
37. Statin-fibrate combination for mixed dyslipidaemia: a limited option?
Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
Curr Med Res Opin; 2010 Sep; 26(9):2137-40. PubMed ID: 20662560
[TBL] [Abstract][Full Text] [Related]
38. Fibrates in the management of atherogenic dyslipidemia.
Okopień B; Buldak L; Bołdys A
Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
[TBL] [Abstract][Full Text] [Related]
39. Benefits and risks of the treatment with fibrates--a comprehensive summary.
Okopień B; Bułdak Ł; Bołdys A
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
[TBL] [Abstract][Full Text] [Related]
40. [Drug combinations: statins and fibrates].
Xavier HT
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():34-5. PubMed ID: 16400396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
